Research - The first of two phase 2 trials testing GlobeImmune’s (GBIM) GS-4774, an immunotherapy directed towards Hepatitis B and partnered with Gilead Sciences (GILD), has failed. The stock … Continue Reading
Read NowResearch - It’s been almost 30 years since the U.S. FDA approved the first statin to lower cholesterol, and the class remains the go-to therapy for treating hypercholesterolemia.
Premium: Read NowResearch - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
Premium: Read NowResearch - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read NowResearch - Our suggestion in November was to be long GBIM from below $6.00 in anticipation of data this quarter for GS-4774. We're up 75%. Here's what to do next.
Premium: Read NowResearch - Great news for our suggested uniQure (QURE) position – Bristol-Myers Squibb (BMY) is putting up $100 million upfront to partner with the European gene therapy developer … Continue Reading
Premium: Read NowResearch - Trillium Therapeutics raised approximately $50 million in a secondary offering this week. The company is well-financed through 2016 and initial (critical) data on lead program, SIRPaFc. … Continue Reading
Premium: Read Now
